LON:APH Alliance Pharma (APH) Share Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free APH Stock Alerts GBX 34.95 +0.05 (+0.14%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range 34.45▼ 35.7550-Day Range 34.90▼ 44.8052-Week Range 33.70▼ 73.04Volume296,565 shsAverage Volume800,455 shsMarket Capitalization£188.87 millionP/E RatioN/ADividend Yield5.72%Price TargetGBX 80.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider Trades Get Alliance Pharma alerts: Email Address Alliance Pharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside131.0% UpsideGBX 80.75 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.34 out of 5 stars 3.4 Analyst's Opinion Consensus RatingAlliance Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAlliance Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for APH. Previous Next 1.7 Dividend Strength Dividend LeadershipAlliance Pharma is a leading dividend payer. It pays a dividend yield of 3.75%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthAlliance Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APH. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Alliance Pharma this week, compared to 0 articles on an average week.Search InterestOnly 9 people have searched for APH on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alliance Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders11.74% of the stock of Alliance Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.04% of the stock of Alliance Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Alliance Pharma is -3,495.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alliance Pharma is -3,495.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAlliance Pharma has a PEG Ratio of 1.04. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioAlliance Pharma has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Alliance Pharma Stock (LON:APH)Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics. It provides its products under the Aloclair, Anbesol, Asthon and Parsons, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. Alliance Pharma plc was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.Read More APH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APH Stock News HeadlinesApril 24, 2024 | americanbankingnews.comAlliance Pharma (LON:APH) Stock Price Passes Below 200-Day Moving Average of $38.67April 17, 2024 | tmcnet.comAphaia Pharma to Participate in a Panel Discussion at the 10th LSX World CongressApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? April 16, 2024 | americanbankingnews.comAlliance Pharma (LON:APH) Shares Cross Below 200-Day Moving Average of $39.04February 5, 2024 | msn.comHealthcare firm Alliance Pharma appoints new chairJanuary 31, 2024 | lse.co.ukLONDON BROKER RATINGS: Jefferies raises Spirax-Sarco; cuts VictrexJanuary 15, 2024 | finance.yahoo.comInvestors in Alliance Pharma (LON:APH) have unfortunately lost 52% over the last three yearsNovember 30, 2023 | markets.businessinsider.comAscendis Pharma’s Growth Potential Bolstered by Strategic Partnership and Product PipelineApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? November 23, 2023 | morningstar.comAlliance Pharma PLC APHNovember 11, 2023 | uk.investing.comAlliance Pharma (ALAPH)October 19, 2023 | finance.yahoo.comCalculating The Intrinsic Value Of Alliance Pharma plc (LON:APH)June 2, 2023 | fool.co.ukShould you invest in Mark Slater favourite Alliance Pharma right now?May 28, 2023 | msn.comNumis Reiterates Alliance Pharma (LSE:APH) Buy RecommendationMarch 24, 2023 | finance.yahoo.comEarnings Miss: Alliance Pharma plc Missed EPS By 95% And Analysts Are Revising Their ForecastsMarch 18, 2023 | fool.co.uk3 dirt cheap growth shares to buy right now?February 9, 2023 | finance.yahoo.comAlliance Pharma plc's (LON:APH) On An Uptrend But Financial Prospects Look Pretty Weak: Is The Stock Overpriced?January 19, 2023 | finance.yahoo.comIs Alliance Pharma plc (LON:APH) Trading At A 49% Discount?December 3, 2022 | finance.yahoo.comAlliance Pharma plc (LON:APH) is a favorite amongst institutional investors who own 85%October 24, 2022 | finance.yahoo.comShareholders in Alliance Pharma (LON:APH) are in the red if they invested a year agoSeptember 20, 2022 | finance.yahoo.comEdited Transcript of ALAPH.L earnings conference call or presentation 20-Sep-22 8:30am GMTSeptember 7, 2022 | apnews.comLove Pharma Initiates First Steps Towards a Strategic Alliance with Starton Therapeutics with Investment in this Biotech LeaderSeptember 2, 2022 | fool.co.ukAlliance PharmaSeptember 2, 2022 | finance.yahoo.comAre Alliance Pharma plc's (LON:APH) Mixed Financials Driving The Negative Sentiment?August 13, 2022 | marketwatch.comU.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into AustraliaAugust 8, 2022 | marketwatch.comAlliance Pharma Names New Auditor After KPMG Resigns Over Corporate ConcernsJune 2, 2022 | uk.finance.yahoo.comThe Alliance Pharma share price – where next?See More Headlines Receive APH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alliance Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:APH CUSIPN/A CIKN/A Webwww.alliancepharma.co.uk Phone+44-1249-466966FaxN/AEmployees285Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 80.75 High Stock Price TargetGBX 105 Low Stock Price TargetGBX 53 Potential Upside/Downside+130.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E Ratio7.89 P/E Growth1.04Net Income£-7,060,000.00 Net Margins-4.15% Pretax MarginN/A Return on Equity-2.46% Return on Assets2.99% Debt Debt-to-Equity Ratio45.00 Current Ratio1.93 Quick Ratio1.42 Sales & Book Value Annual Sales£170.05 million Price / Sales1.11 Cash FlowGBX 4.45 per share Price / Cash Flow7.87 Book ValueGBX 51 per share Price / Book0.69Miscellaneous Outstanding Shares540,400,000Free FloatN/AMarket Cap£189.01 million OptionableNot Optionable Beta0.60 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Andrew Timothy Franklin (Age 58)Interim CEO, CFO & Executive Director Comp: $271.52kMr. Peter Jonathan Butterfield (Age 48)CEO & Executive Director (Leave of Absence) Comp: $399.83kMr. Jeyan Heper (Hons) (Age 50)BA, COO & Director Mr. Stephen KidnerChief Scientific Affairs OfficerMs. Cora Maeve McCallum C.F.A.Head of Investor Relations & Corporate CommunicationsMr. Christodoulos Theoclis ChrysanthouGroup General Counsel & Company SecretaryMr. Alex DugganChief Commercial & Corporate Development OfficerJulie SkinnerChief People OfficerChris DelafieldGlobal Marketing Head of Kelo-CoteRhodri SmithHead of SourcingMore ExecutivesKey CompetitorsBeximco PharmaceuticalsLON:BXPAllergy TherapeuticsLON:AGYAnimalcare GroupLON:ANCRCeladon PharmaceuticalsLON:CELECO Animal Health GroupLON:EAHView All CompetitorsInsidersAndrew FranklinSold 42,053 sharesTotal: £1.64 M ($39.00/share)Jo Le CouilliardBought 40,957 shares on 7/20/2023Total: £2.01 M ($49.00/share)Andrew FranklinBought 50,988 shares on 7/18/2023Total: £2.50 M ($49.00/share)View All Insider Transactions APH Stock Analysis - Frequently Asked Questions Should I buy or sell Alliance Pharma stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alliance Pharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APH shares. View APH analyst ratings or view top-rated stocks. What is Alliance Pharma's stock price target for 2024? 4 analysts have issued 12 month target prices for Alliance Pharma's shares. Their APH share price targets range from GBX 53 to GBX 105. On average, they predict the company's share price to reach GBX 80.75 in the next year. This suggests a possible upside of 131.0% from the stock's current price. View analysts price targets for APH or view top-rated stocks among Wall Street analysts. How have APH shares performed in 2024? Alliance Pharma's stock was trading at GBX 40.50 at the beginning of 2024. Since then, APH stock has decreased by 13.7% and is now trading at GBX 34.95. View the best growth stocks for 2024 here. Is Alliance Pharma a good dividend stock? Alliance Pharma (LON:APH) pays an annual dividend of GBX 2 per share and currently has a dividend yield of 3.75%. Read our dividend analysis for APH. What other stocks do shareholders of Alliance Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alliance Pharma investors own include RPC Group (RPC), American Airlines Group (AAL), BlackBerry (BB), Editas Medicine (EDIT), 1-800-FLOWERS.COM (FLWS), Air Canada (AC), Ally Financial (ALLY), Aviva (AV), BAE Systems (BA) and Berry Global Group (BERY). How do I buy shares of Alliance Pharma? Shares of APH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:APH) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alliance Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
